From: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Univariate | Full Multivariate | Parsimonious | ||||||
---|---|---|---|---|---|---|---|---|
Model | Variable | RR (95% CI) | P | RR (95% CI) | P | RR (95% CI) | P | |
Model 1 | CK5/6+ and/or EGFR+ | No | 1. | 1. | ||||
Yes | 2.24 [1.14; 4.39] | 0.02 | 1.20 [0.50; 2.85] | 0.68 | not present | |||
TNP | No | 1. | 1. | 1. | ||||
Yes | 4.06 [2.11; 7.82] | 0.0001 | 3.42 [1.37; 8.49] | 0.008 | 4.40 [2.23; 8.69] | 0.0001 | ||
Model 2 | PR | No | 1. | 1. | ||||
Yes | 0.43 [0.23; 0.81] | 0.009 | 0.70 [0.34; 1.45] | 0.34 | not present | |||
CBP | No | 1. | 1. | 1. | ||||
Yes | 3.73 [1.88; 7.39] | 0.0002 | 3.13 [1.26; 7.77] | 0.01 | 4.29 [2.12; 8.68] | 0.0001 | ||
Model 3 | ER- HER2- | No | 1. | 1. | 1. | |||
Yes | 4.39 [2.34; 8.23] | 0.0001 | 4.82 [1.95; 11.9] | 0.0006 | 5.38 [2.77; 10.5] | 0.0001 | ||
PR | No | 1. | 1. | |||||
Yes | 0.43 [0.23; 0.81] | 0.009 | 0.82 [0.38; 1.76] | 0.61 | not present | |||
CK5/6+ and/or EGFR+ | No | 1. | 1. | |||||
Yes | 2.24 [1.14; 4.39] | 0.02 | 0.99 [0.42; 2.34] | 0.98 | not present |